Sinarx Pharmaceuticals LLC

Rexahn Pharmaceuticals is a biopharmaceutical company based in Germantown, MD, dedicated to developing innovative therapies for cancer treatment. With a focus on radiation oncology and immuno-oncology, their groundbreaking products aim to cure cancer and enhance patient outcomes by sensitizing cancer cells, protecting normal tissues, and monitoring clinical responses to treatment. Driven by a world-class team of scientific, clinical, and regulatory experts, including co-founders Dr. Anatoly Dritschilo, Dr. Milton Brown, and Dr. Mira Jung, Rexahn Pharmaceuticals has built a robust platform technology for the discovery and development of novel small molecules. Through strategic collaborations and a portfolio of lead clinical-stage and pre-clinical products, they are at the forefront of advancing the field of radiation oncology and revolutionizing cancer therapy.Generated from the website

GlycoMimetics, Inc. is a biotechnology company based in Gaithersburg, Maryland, dedicated to providing valuable information about its business to stockholders, potential investors, and financial analysts. The company's Investor Relations website serves as a comprehensive resource for those seeking insights into GlycoMimetics' operations and financial performance. With a focus on transparency and communication, GlycoMimetics aims to keep stakeholders informed and engaged through its Investor Relations platform. By offering detailed information and updates, the company strives to foster trust and understanding among its investor community. Generated from their website's infomation

Dexorgen, Inc. is an advanced biotechnology company based in Gaithersburg, MD, specializing in providing simple and high throughput solutions for drug discovery. With their patented ACTOne technology, they offer live cell based assays for efficient screenings of new compounds in a physiologically accurate environment, making them a leader in the production of commercially available cell lines that target phosphodiesterases (PDEs). Dexorgen also offers unique biochemical assay kits and specialty dyes, aiming to deliver high-quality products that aid scientists in the discovery process. With a strong focus on compound screening and target selectivity profiling, Dexorgen provides a range of services including assay development, mechanism of action characterization, reagent development, primary cell culture, and cell engineering. They have actively participated in federal collaborations such as Tox21, developing assays for nuclear hormone receptors and mitochondria toxicity, and are currently working on evaluating toxicities on TSHR and TRHR. Dexorgen collaborates with pharmaceutical companies, biotech companies, universities, and governmental institutes, offering their expertise and innovative solutions to advance scientific research.Generated from the website